Myelodysplastic Syndromes: all 2,165 studies

Page 7 of 22. Open to participants first (322), then studies with results posted, then the rest; newest registration first within each.

• Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T CellCompletedNCT01660607Phase 1/2Results posted
• Busulfan/Clofarabine + Allogeneic Stem Cell TransplantationCompletedNCT01643668Phase 2Results posted
• T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic TransplantTerminatedNCT01621477Phase 2Results posted
• Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaTerminatedNCT01620216Phase 2Results posted
• Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TARCompletedNCT01611298Not applicableResults posted
• Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDSTerminatedNCT01607645Phase 2Results posted
• Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic SyndromeCompletedNCT01599325Phase 2Results posted
• Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible DonorTerminatedNCT01598025Not applicableResults posted
• Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic SyndromesCompletedNCT01593670Phase 2Results posted
• Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine ConditioningCompletedNCT01572662Phase 2Results posted
• The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)CompletedNCT01566695Phase 3Results posted
• Rasburicase and Allopurinol in Treating Patients With Hematologic MalignanciesTerminatedNCT01564277Phase 2Results posted
• A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01546038Phase 2Results posted
• Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)TerminatedNCT01542684Phase 2Results posted
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 2Results posted
• Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT01522976Phase 2Results posted
• A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic SyndromeTerminatedNCT01513317Phase 2Results posted
• Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell TransplantationCompletedNCT01491958Phase 2Results posted
• A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic LeukemiaTerminatedNCT01486784Phase 1/2Results posted
• Safety and Tolerability of HSC835 in Patients With Hematological MalignanciesCompletedNCT01474681Phase 1/2Results posted
• Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)CompletedNCT01471444Phase 3Results posted
• Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in RemissionTerminatedNCT01465386Phase 2Results posted
• Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)CompletedNCT01444742Phase 2Results posted
• Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDSTerminatedNCT01442714Phase 2Results posted
• A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid LeukemiaCompletedNCT01440374Phase 2Results posted
• SB1518 for Patients With Myelodysplastic Syndrome (MDS)TerminatedNCT01436084Phase 2Results posted
• Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesCompletedNCT01427881Phase 2Results posted
• Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT01420926Phase 2Results posted
• Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative DisordersCompletedNCT01392989Phase 2Results posted
• A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic SyndromesTerminatedNCT01379274Phase 2Results posted
• Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT01378416Phase 1Results posted
• NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid DiseasesCompletedNCT01370213Phase 2Results posted
• Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body IrradiationTerminatedNCT01366612Phase 3Results posted
• Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)CompletedNCT01362140Phase 3Results posted
• Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two StepsTerminatedNCT01350258Phase 1/2Results posted
• Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative DonorCompletedNCT01350245Phase 2Results posted
• Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01349972Phase 2Results posted
• Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)TerminatedNCT01339910Phase 3Results posted
• Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow TransplantationCompletedNCT01338987Phase 2Results posted
• Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic DiseasesCompletedNCT01336712Phase 2Results posted
• Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability StudyTerminatedNCT01326845Phase 4Results posted
• Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related DonorsCompletedNCT01323920Phase 2Results posted
• Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell TransplantCompletedNCT01305200Phase 3Results posted
• Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDSCompletedNCT01300572Phase 1Results posted
• Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)CompletedNCT01295710Phase 3Results posted
• Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs VidazaCompletedNCT01290302Phase 1Results posted
• Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic SyndromeCompletedNCT01289457Phase 1/2Results posted
• Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766Phase 2Results posted
• Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)CompletedNCT01272245Phase 2Results posted
• SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)CompletedNCT01261312Phase 1/2Results posted
• Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic SyndromeCompletedNCT01254890Phase 1/2Results posted
• Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantCompletedNCT01251575Phase 2Results posted
• Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating AgentsCompletedNCT01246076Phase 2Results posted
• Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01238211Phase 2Results posted
• Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic CancerCompletedNCT01233921Not applicableResults posted
• Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell TransplantCompletedNCT01231412Phase 3Results posted
• Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)TerminatedNCT01222195Phase 2Results posted
• Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological MalignanciesCompletedNCT01221857Phase 1/2Results posted
• Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)CompletedNCT01201811Phase 4Results posted
• Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic SyndromeCompletedNCT01200355Phase 4Results posted
• Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)TerminatedNCT01191749Phase 2Results posted
• Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic MalignanciesCompletedNCT01188798Phase 3Results posted
• An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)CompletedNCT01186939Phase 3Results posted
• Revlimid in Transfusion Dependent PatientsCompletedNCT01178814Phase 2Results posted
• Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid LeukemiaCompletedNCT01168219Phase 2Results posted
• Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic SyndromeCompletedNCT01165996Phase 1/2Results posted
• Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadTerminatedNCT01159067Phase 2Results posted
• Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling DonorsCompletedNCT01158118Phase 2Results posted
• Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDSCompletedNCT01141725Phase 1/2Results posted
• Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic CancersTerminatedNCT01135329Phase 2Results posted
• Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDSCompletedNCT01133275Phase 2Results posted
• HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic MalignanciesCompletedNCT01119066Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell TransplantTerminatedNCT01118013Phase 2Results posted
• Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell TransplantationTerminatedNCT01116232Phase 2Results posted
• Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative NeoplasmCompletedNCT01101880Phase 2Results posted
• Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients?CompletedNCT01099917Phase 2Results posted
• Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003CompletedNCT01099267Results posted
• Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01093586Phase 2Results posted
• Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell TransplantCompletedNCT01083706Phase 2Results posted
• Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTerminatedNCT01076270Not applicableResults posted
• Exjade-Early-TrialTerminatedNCT01058369Phase 2Results posted
• Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cellsTerminatedNCT01050764Phase 1/2Results posted
• Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic CancerTerminatedNCT01044745Phase 2Results posted
• 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)CompletedNCT01038635Phase 1/2Results posted
• A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic MalignanciesCompletedNCT01036009Phase 2Results posted
• LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)TerminatedNCT01034657Phase 2Results posted
• Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent AnemiaTerminatedNCT01034592Phase 1Results posted
• A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5qCompletedNCT01029262Phase 3Results posted
• Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTerminatedNCT01028716Phase 2Results posted
• Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)CompletedNCT01019317Phase 2Results posted
• Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCTCompletedNCT01012492Phase 2Results posted
• To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.TerminatedNCT01011283Phase 4Results posted
• Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic SyndromesTerminatedNCT00997243Phase 2Results posted
• Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and FludarabineCompletedNCT00987480Phase 2Results posted
• Erlotinib Study for Myelodysplastic Syndrome (MDS)CompletedNCT00977548Phase 2Results posted
• T-cell Depleted Alternative Donor TransplantationTerminatedNCT00968864Phase 2Results posted
• Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic SyndromeCompletedNCT00968071Phase 2Results posted
• Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical DonorTerminatedNCT00967343Phase 2/3Results posted
• Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic CancerTerminatedNCT00963872Phase 1/2Results posted
• A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)CompletedNCT00961064Phase 2Results posted

← Myelodysplastic Syndromes overview